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Abstract: Angiotensin receptor blockers have emerged as a first-line therapy in the   management 
of hypertension and hypertension-related comorbidities. Since national and international 
  guidelines have stressed the need to control blood pressure to ,140/90 mmHg in uncomplicated 
hypertension and ,130/80 mmHg in those with associated comorbidities such as diabetes or 
chronic kidney disease, these goal blood pressures can only be achieved through combination 
therapy. Of several drugs that can be effectively combined to attain the recommended blood 
pressure goals, fixed-dose combinations of angiotensin receptor blockers and the calcium channel 
blocker amlodipine provide additive antihypertensive effects associated with a safe profile and 
increased adherence to therapy. In this article, we review the evidence regarding the beneficial 
effects of renin–angiotensin system blockade with olmesartan medoxomil and amlodipine in terms 
of blood pressure control and improvement of vascular function and target organ damage.
Keywords: amlodipine, angiotensin receptor blockers, angiotensin-converting enzyme 2, 
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Introduction
The 33rd report on the Health Status in the United States estimates that essential 
hypertension affects 17.9% of the age-adjusted, 20-year-old or older white subjects 
and up to 26% of male African Americans (http://www.cdc.gov/nchs/data/hus/hus09.
pdf). Numerous large-scale clinical trials have documented the benefits of strict blood 
pressure control in preventing hypertension-related cardiovascular events. It is clear 
that the benefit of blood pressure reduction to 120/80 mmHg in non-diabetic patients   
will be associated with a large reduction in the occurrence of strokes and fatal and 
nonfatal ischemic heart diseases. Since single-drug therapy is often not able to lower 
blood pressure to these ideal values, recent recommendations now emphasize the need 
for combination therapy to achieve these blood pressure goals.1,2 Although no definitive 
evidence is available as to which combination therapy will most effectively achieve 
strict blood pressure control and reduction in target organ damage, the increased use 
of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers 
(ARBs), and the calcium channel blocker (CCB) amlodipine, widely prescribed alone 
or in combination in most countries in the world, favors their use.
Evidence-based medicine from large controlled clinical trials supports the use of 
these drugs, although the long-term benefit of any one combination over the others 
remains to be established.3 In this context, the Avoiding Cardiovascular Events through 
COMbination Therapy in Patients LIving with Systolic Hypertension   (ACCOMPLISH) 
study showed that the combination of benazepril and amlodipine resulted in outcome Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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benefits greater than those observed in subjects medicated 
with benazepril and hydrochlorothiazide (HCTZ) despite 
similar blood pressure reductions.4,5 Although both ACE 
inhibitors and ARBs have a definitive role in preventing the 
consequences of increased renin–angiotensin system activity 
in cardiac, vascular, and renal functions, enhanced tolerability 
and the more specific effects of ARBs on suppressing the 
binding of angiotensin II (Ang II) to the subtype 1 (AT1) 
receptor should favor the use of ARBs over blockers of ACE. 
This article summarizes the evidence for the combined use of 
the AT1 selective receptor antagonist, olmesartan medoxomil, 
with amlodipine on blood pressure control and target organ 
damage. Additional information regarding the pharmacologi-
cal and clinical response to olmesartan administration are 
reviewed elsewhere.6–9
Pharmacodynamics of olmesartan 
and amlodipine
Olmesartan medoxomil is a highly selective ARB with 
  pharmacokinetic characteristics that determine high binding 
to AT1 receptors and lasting effects on arterial pressure.10,11 
The medoxomil ester of olmesartan facilitates its bioavailabil-
ity as the oral bioavailability of the active product RNA-6270 
is less than 4.5%.12 In bovine adrenal cells, the displacement 
of 125I-Ang II by olmesartan has an half maximal inhibitory 
concentration (IC50) value of 7.7 nM, a displacement value 
significantly lower than that of losartan (92 nM) and its active 
metabolite EXP3174 (16 nM). Figure 1 shows that the   affinity 
of olmesartan for AT1 receptors is high when compared 
with that of other ARBs. Furthermore, the   displacement of 
olmesartan by Ang II in Hill’s plots shows that the active 
drug behaves as a competitive antagonist of AT1   receptors.13 
Pharmacokinetic properties of olmesartan support its 
efficacy and long duration of action when given to experi-
mental animals and humans. Additional information on 
  pharmacokinetics of olmesartan and its mode of action are 
discussed elsewhere.8,9,14
The antihypertensive actions of olmesartan are   potentiated 
when used in combination with either thiazide diuretics or 
CCBs. Amlodipine is a potent dihydropyridine CCB   having 
a high degree of ionization, high oral bioavailability (60%–
65%), and peak plasma concentrations attainable within 6–8 
hours after oral administration. Like other   dihydropyridine 
CCB, amlodipine selectively inhibits   calcium (Ca2+) influx 
across cell membranes in cardiac and vascular smooth 
muscle with a greater effect on the latter.15 Rohatagi et al16 
reported the pharmacokinetics of   olmesartan medoxomil and 
amlodipine besylate alone and in a fixed-dose combination 
in five phase I crossover studies in healthy volunteers. The 
similarity of the mean steady-state pharmacokinetics of olm-
esartan and amlodipine at doses of 40 and 10 mg, respectively, 
their drug concentration–time curves, and the maximum 
observed plasma drug concentrations within their prespeci-
fied bioequivalence (80%–125%) showed that they were well 
suited to coadministration in a fixed-dose combination.16 
Furthermore, coadministration of amlodipine besylate and 
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Figure 1 Comparative pharmacodynamic characteristics of five angiotensin receptor blockers in terms of their half maximal inhibitory concentration (IC50) and dissociation 
constant (Ki). The active form of olmesartan shows high affinity for AT1 receptors with an iC50 equivalent to that of candesartan and much lower than the iC50 for other 
angiotensin receptor blockers. Similarly, the lowest iC50 for olmesartan is associated with the lowest dissociation constant from the receptor.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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olmesartan medoxomil, as commercially available separate 
dosage forms, for 10 days showed no evidence of any negative 
pharmacokinetic drug–drug interactions.16
The additive mechanisms of action of the single-dose 
form of olmesartan/amlodipine on long-term hemodynamic 
and neurohormonal systems controlling blood pressure have 
not been studied. Results from the direct effects of   olmesartan 
or amlodipine on cardiac and vascular structures and hyper-
tension-induced remodeling suggest complementary actions. 
Olmesartan induces a reduction in peripheral vascular resis-
tance that is associated with no changes in heart rate or cardiac 
output and increases in plasma renin activity (see Schindler 
and Ferrario9 for review). In the EUropean Trial on Olm-
esartan and Pravastatin in Inflammation and Atherosclerosis 
(EUTOPIA trial),17 olmesartan was found to lower the serum 
levels of high-sensitivity C-reactive   protein, tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6), and human monocyte 
chemoattractant protein-1 (MCP-1). A further reevaluation of 
the EUTOPIA trial showed that the vasculoprotective effects 
of olmesartan were associated with decreases in plasma 
osteopontin concentrations.18 The anti-inflammatory effects of 
AT1 receptor blockade with olmesartan may contribute to the 
observation that this drug can prevent the progression of ath-
erosclerosis in nonhuman primates.19 Additional vasculotropic 
effects of olmesartan in the protection of vascular endothelial 
function have been reviewed recently.8 Although the long-term 
effect of   olmesartan on the plasma and tissue concentrations 
of Ang II requires further study, a report by Ichikawa et al20 
showed that blockade of AT1 receptors may not be   associated 
with the typical increase in plasma Ang II concentrations, as 
observed with other ARBs.21 This clinical study may be tenta-
tively explained by the observation that AT1 blockade upregu-
lates the activity and tissue expression of ACE 2, a homolog 
of ACE that acts as a monocarboxypeptidase degrading Ang II 
into the vasodilator and antitrophic peptide angiotensin-(1-7) 
[Ang-(1-7)].22–27 In keeping with these findings, an experimen-
tal study in the stroke-prone rat suggested that olmesartan may 
act as an inhibitor of ACE through the stimulation of Ang-(1-7) 
actions and release of nitric oxide.28
The beneficial effects of olmesartan on the prevention 
of vascular remodeling and carotid artery atherosclerotic 
plaque progression in subjects with hypertension are now 
documented.29,30 The Multicentre Olmesartan atherosclerosis 
Regression Evaluation (MORE) study was a double-blind 
trial conducted in patients with hypertension who are at 
increased cardiovascular risk (presence of carotid wall 
thickening and a defined atherosclerotic plaque), using 
noninvasive two- and three-dimensional ultrasonography. 
The trial compared the effects of a 48-month treatment based 
on either olmesartan medoxomil or atenolol on common 
carotid intima-media thickness and plaque volume (PV).30 
Large PVs (.33 µL) were significantly reduced over the 102-
week treatment period only in those subjects assigned to the 
olmesartan-based therapy. In agreement with these findings, 
administration of olmesartan to subjects with diabetes was 
associated with reduced arterial stiffness while amlodipine 
had no effect.31
The Vascular Improvement with Olmesartan Study (VIOS) 
enrolled 100 subjects with stage 1 hypertension without diabe-
tes, to evaluate whether an olmesartan-based therapeutic regi-
men could reverse vascular hypertrophy independent of the 
magnitude of blood pressure lowering.29,32 The trial compared 
the effects of olmesartan-based therapy versus atenolol-based 
therapy on blood pressure control and changes in wall/media 
lumen (W/L) ratio from small resistance arterioles obtained 
from these patients through the technique of gluteal biop-
sies.32–34 Biopsies were available from 22 atenolol recipients 
(100 mg/day), 27 olmesartan medoxomil recipients (40 mg/
day), and 11 normal volunteer controls. Additional antihy-
pertensive medications (HCTZ 12.5–25 mg/day, amlodipine 
5–10 mg/day, or hydralazine 50–100 mg twice daily) were 
dispensed to achieve blood pressure control below 140/90 
mmHg. Overall, patients in the atenolol-based regimen group 
required more medications versus patients randomized to the 
olmesartan-based group. Furthermore, a greater percentage 
of patients assigned to the olmesartan-based therapy achieved 
and maintained an ideal blood pressure of #120/80 mmHg 
at 4 weeks (24% in the olmesartan-based therapy vs 8% in 
those assigned to the atenolol-based therapy [P , 0.05]). At 
the completion of the 52-week period, comparable decreases 
in arterial   pressure resulting in the physiological levels of 
blood pressure (#120/80 mmHg) were observed in patients 
assigned to each of the two regimens. Normalization of 
blood pressure, however, was associated with the regression 
of vascular hypertrophy only in those subjects assigned to 
the olmesartan-based therapy (Figure 2). In these subjects, 
the reduction in W/L ratio of small resistance vessels (from 
14.9% to 11.1%; P , 0.01) was numerically equivalent to 
the W/L ratio determined in the subset of normotensive vol-
unteers from whom subcutaneous small arteriole resistance 
vessels were obtained.32 Since the addition of HCTZ and 
amlodipine were required in more than 59% of the subjects 
and no   differences existed in the dosing and time periods in 
which these agents were incorporated to the treatment regimen Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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for both arms of the study, the data demonstrated that the 
selective effect of AT1 receptor blockade in the reversal of 
vascular hypertrophy in small resistance vessels was directly 
responsible for the reduction of peripheral vascular resis-
tance.32,33 Furthermore, noninvasive measurements of central 
aortic pressure and determination of the augmentation index 
by applanation tonometry35 showed decreases in the indices 
of vascular compliance only on those subjects receiving the 
olmesartan-based therapy.32 On the other hand, a study that 
investigated the role of cellular oxidant stress and inflamma-
tion on patients with hypertension and the cardiometabolic 
syndrome showed comparative effects induced by treatment 
with either olmesartan or amlodipine.36 A small sample size 
and the presence of comorbidities may have contributed to 
the reported conclusions.36
Clinical studies
A series of studies have documented the effective control 
of arterial pressure achieved with the daily fixed-dose 
  administration of a single tablet of olmesartan/amlodipine. 
A multicenter, double-blind, randomized, placebo-controlled, 
parallel-group, factorial study, lasting 8 weeks and   enrolling 
1,940 subjects with stage 1 and stage 2 hypertension, 
  evaluated the blood pressure response to placebo,   amlodipine 
(5–10 mg/day), olmesartan (10, 20, and 40 mg/day), and the 
fixed combination of olmesartan and amlodipine at doses 
of 5/10, 5/20, 5/40, 10/10, 10/20, and 10/40 mg/day.37 At 
the highest dose combination of olmesartan/amlodipine 
(40/10 mg/day), the reduction in systolic and diastolic blood 
pressures amounted to 28.5 and 19.4 mmHg, respectively.37 
The decreases in arterial pressure were significantly greater 
than those obtained with either olmesartan or amlodipine 
when given alone.37 The beneficial effects of the single-tablet 
combination were associated with increased target blood pres-
sure of ,140/90 mmHg.37 Although all treatment regimens in 
the Combination of Olmesartan medoxomil and Amlodipine 
besylate in Controlling High blood pressure (COACH) study 
were well tolerated and were free of major side effects, the 
occurrence of pedal edema was less in those subjects medi-
cated with the fixed-dose combination of 40/10 mg of olm-
esartan/amlodipine (23.5%) than in those subjects medicated 
with amlodipine alone (36.8%). The reduction in peripheral 
edema in response to the addition of an ARB to a CCB is a 
product of the concurrent vasodilator effect of Ang II blockade 
inducing venular capillary dilatation, thus diminishing the 
pressure gradient across the peripheral microcirculation.38
A trial performed in Europe compared the effectiveness of 
a single-pill combination of olmesartan and amlodipine in a 
randomized, double-blind, parallel-group, multicenter trial in 
patients with moderate to severe hypertension   (systolic blood 
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Figure 2 Bar graph denotes the average value of wall/media lumen ratio from small resistance arterioles obtained from normotensive subjects (normal) and patients with 
hypertension without diabetes assigned to either an atenolol-based or olmesartan-based therapy before and at week 52 after completion of the treatment regimen. 
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pressure [SBP] $160 mmHg and diastolic blood   pressure 
[DBP] $100 mmHg).39 Nonresponders to an open-label 
monotherapy phase with olmesartan (8 weeks at 20 mg/day) 
were randomized to 20 mg/day olmesartan plus placebo, the 
fixed-dose combination of 20 mg/day olmesartan plus 5 mg/
day amlodipine, or 20 mg/day olmesartan plus 10 mg/day 
amlodipine for an additional 8 weeks.39 The primary end 
point evaluated the intention-to-treat population of all sub-
jects with hypertension who received at least one dose of 
the double-blind study medication, had baseline measures 
of sitting DBP, and received at least one postrandomization 
measure of DBP . 140/90 mmHg. Potential confounders 
due to the use of the less rigorous statistical approach of 
last observation carried forward for missing data during the 
double-blind period were compensated by the inclusion of an 
observed case approach in which the last observation was not 
carried forward. Of the 1,519 screened subjects, 722 patients 
entered the open-label phase of the study with 20 mg/day 
olmesartan. The 538 subjects who completed this phase 
of the study were randomized to the 8-week double-blind 
period of one of the three interventions. The blood pressure 
of ,140/90 mmHg after the 8-week double-blind period was 
achieved in 28.5%, 44.5%, and 45.8% of subjects randomized 
to olmesartan/placebo, 20/5 mg/day olmesartan/amlodipine, 
and 20/10 mg/day olmesartan/amlodipine, respectively.39 
A post hoc analysis showed that the number of subjects 
reaching a DBP of ,90 mmHg were greater in those using 
the fixed-dose combinations of olmesartan/  amlodipine.39 In 
addition, the study showed that the combination therapy was 
associated with an earlier reaching of their goal blood pres-
sure when compared with the monotherapy phase. These data 
are in agreement with another study in which the combina-
tion of 10–40 mg/day olmesartan with 5 mg/day amlodipine 
for 8 weeks reduced the mean SBP and DBP by 16.8 and 
9.6 mmHg, respectively.40
SBP is a predictor of increased cardiovascular risk.41 In a 
post hoc analysis of changes in sitting SBP in patients treated 
with 40 mg of olmesartan plus 5–10 mg/day amlodipine,40 
the combination therapy was shown to be most effective in 
reducing SBP in the subjects with highest levels of SBP.42 As 
reviewed elsewhere,43 this combination therapy is superior 
to the single-agent administration in other high-risk popula-
tions, such as African Americans,44 obese, and patients with 
diabetes. The predominant effect of improvement in insulin 
resistance and reduced oxidative stress seems to be related 
to blockade of Ang II receptors.45–49
Presence of chronic kidney disease aggravates the odds 
of cardiovascular events in patients with hypertension.50 
The potential for renoprotective effects of combining a 
CCB with olmesartan in elderly patients (age 65–85 years) 
with chronic kidney disease was investigated in a crossover 
study using an open-label, randomized design with albu-
minuria (creatinine . 5 mg/g).51 Following a 2-week run in 
observation period, the subjects were randomized to receive 
a starting dose of benidipine (4 mg/day) or amlodipine com-
bined with olmesartan (5/10 mg/day). Three months later, 
the patients were switched from benidipine to amlodipine 
and followed-up for an additional 3 months. Benidipine 
is a dihydropyridine CCB that induces efferent arteriolar 
dilation through blockade of both L- and T-type calcium 
channels.52,53 Combination of olmesartan with either CCBs 
produced comparable decreases in arterial blood pressure, 
whereas the combination of benidipine and olmesartan 
achieved slightly greater statistically significant decreases 
in albumin excretion.51 The Randomized Olmesartan and 
Diabetes Prevention (ROADMAP) study determined the 
factors correlating with albumin excretion rates across the 
range of normoalbuminuric values in patients with type 2 
diabetes using olmesartan medoxomil.54,55
There is evidence that the administration of olmesartan 
is the key driver in achieving the target blood pressure in 
patients with stage II hypertension56 and reducing the effects 
of hypertension in vascular remodeling.31,32 A multicenter, 
12-week study compared the efficacy, safety, and tolerability 
of a combination of olmesartan medoxomil/HCTZ with that 
of benazepril plus amlodipine besylate in patients with stage 
II hypertension.57 The data showed that the primary efficacy 
end point of change in mean seated SBP at week 12 was 
significantly greater with olmesartan medoxomil/HCTZ 
than with benazepril plus amlodipine besylate.57 These 
findings are in agreement with other studies documenting 
the efficacy of the combination of olmesartan/HCTZ in sub-
jects with hypertension and in those with isolated systolic 
hypertension.44,58–60 As reviewed by Quan et al61 a multi-
factorial analysis of the published studies reported that the 
daily combination of 40 mg olmesartan and 25 mg HCTZ 
produced greater blood pressure reductions than with the 
administration of 300 mg irbesartan/25 mg HCTZ, 80 mg 
telmisartan/12.5 mg HCTZ, and 160 mg valsartan/25 mg 
HCTZ.62 The addition of HCTZ to patients receiving a fixed-
dose combination of olmesartan/amlodipine (40/5–10 mg/
day) increased the overall proportion of patients reach-
ing the goal blood pressure.63 In an additional study that 
focused on reaching the blood pressure goals rather than 
the responder rates, with the combination of olmesartan 
medoxomil, amlodipine, and HCTZ, 90% of patients with Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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stage 2 hypertension reached the blood   pressure of ,140/90 
mmHg and 81% patients attained ,130/85 mmHg.64
Long-term outcome studies as to the benefit of the combina-
tion of olmesartan/amlodipine in the prevention of cardiovascular 
events are not yet available. To meet this objective, an on-going 
study will evaluate whether high-dose ARB monotherapy is 
superior to the combination therapy of ARB plus CCB in the 
prevention of cardiovascular   morbidity and mortality in elderly 
Japanese high-risk patients with hypertension (OlmeSartan and 
Calcium Antagonists Randomized [OSCAR] Study).65
Conclusions
The importance of blood pressure control in the prevention 
of cardiovascular events is well established. Given the rela-
tive success in achieving appropriate blood pressure control 
in the general population, effective drug combinations as 
first-line therapy can meet the need to attain blood pressure 
levels ,140/90 mmHg in uncomplicated hypertension and 
#130/80 mmHg in subjects with diabetes or in those in whom 
hypertension is accompanied by chronic kidney disease. 
Although published guidelines advocate the combination of a 
thiazide diuretic with another antihypertensive agent as initial 
therapy, emerging evidence suggests that the association of a 
CCB with either an ACE inhibitor or an ARB may be a safer 
and more effective combination.66 Evidence for this approach 
is buttressed by the recent publication of the ACCOMPLISH 
study.5 In this study, the combination of the ACE inhibitor 
benazepril with the CCB amlodipine was more effective 
than the combination of benazepril with HCTZ in reducing 
the primary   composite end point of cardiovascular events 
and death from   cardiovascular causes over the 36-month 
mean follow-up period.5 The   combination of olmesartan/
amlodipine in a fixed-dose combination has proven to be 
effective in controlling blood pressure in patients with stage 
1 and stage 2 hypertension.4,37,38,44,56,66–73 Their additive anti-
hypertensive effect is   associated with complimentary actions 
that in part may be related to the buffering of the reactive 
increase in renin–angiotensin system activity triggered by 
the vasodilator action of amlodipine.74
Among the advantages of fixed combination therapy, 
several studies suggest that this approach overcomes issues 
related to side effects, patient and physician inertia, the 
proportion of subjects classified as resistant hypertension, 
and cost-effectiveness issues such as co-pays.43 In   several 
observational studies, fixed-dose combinations were 
associated with higher rates of compliance, persistence, and 
adherence to treatment regimens.75–82 A meta-analysis of 15 
published studies with a total of 32,331 patients concluded 
that fixed-dose combinations of antihypertensive agents were 
associated with increased compliance and no changes in the 
frequency of adverse events when compared with free drug 
components given separately.80
Interest in the effect of the circadian rhythm of blood 
pressure in terms of its association with the occurrence 
of cardiovascular events posits the question as to whether 
  single-pill, fixed-dose combinations may provide greater ben-
efit when administered at bedtime. Although the   effectiveness 
of such a chronotherapeutic approach remains unexplored for 
single-pill, fixed-dose combinations, Minutolo et al83 reported 
that in nondipper subjects with chronic kidney disease 
changing the timing of antihypertensive therapy decreases 
nocturnal blood pressure and proteinuria. As reviewed by 
Stergiou et al84 morning administration of single- or fixed-
dose combinations of drugs have been used in assessing the 
efficacy of antihypertensive therapy. In bedtime dosing of 
treatment as used in the Controlled Onset Verapamil Investi-
gation of Cardiovascular Endpoints (CONVINCE) trial, chro-
notherapeutical dosing of verapamil failed to blunt the early 
morning surge in blood pressure.85 In contrast, the bedtime 
dosing of ramipril in the Heart Outcomes Prevention Evalu-
ation (HOPE) trial has been suggested to partially account 
for the vascular benefits found in this study.86 The efficacy 
of olmesartan medoxomil in controlling blood pressure over 
a 24-hour period showed that the ARB was more effective 
than losartan and valsartan in maintaining lower levels of 
blood pressure for mean daytime and nighttime ambulatory 
blood pressure.87 Although further work will be necessary to 
evaluate these possibilities, it is undeniable that the use of 
a single-pill, fixed-dose combination at bedtime should be 
explored in well-controlled clinical trials.
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